Výsledky vyhledávání - "Aurelia de Vries-Schultink"

Figure S2 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Pharmacokinetics: Z-endoxifen levels per taselisib dose level

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b8c3ce186a1e98a096fd80e837ef085
https://doi.org/10.1158/1078-0432.22471986.v1

Zobrazit plný text záznamu

Figure S3 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Time to progression per patient in a swimmers plot (all patients, N=30)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::033d21c001177dfac27af7e086dc5f60
https://doi.org/10.1158/1078-0432.22471983

Zobrazit plný text záznamu

Data from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Purpose:The strategy of combining endocrine therapy with PI3K-mTOR inhibition has shown promise in estrogen receptor (ER)–positive breast cancer, but new agents and combinations with a better therapeutic index are urgently needed. Taselisib is a po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38dbcd046b3ffe289c7694d6875e0bdd
https://doi.org/10.1158/1078-0432.c.6528075

Zobrazit plný text záznamu

Supplementary Methods from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Supplementary Methods Text

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1182c2cadec2b5dc324fec46d078953
https://doi.org/10.1158/1078-0432.22471977.v1

Zobrazit plný text záznamu

Figure S1 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Taselisib pharmacokinetics in combination with tamoxifen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::141963cc97ce89201fdbae55d0853778
https://doi.org/10.1158/1078-0432.22471989.v1

Zobrazit plný text záznamu

Figure S4 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

PIK3CA mutations detected at baseline (in samples from 8 out of 30 patients)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f51fe6001d7f14498e0dfcb203954c09
https://doi.org/10.1158/1078-0432.22471980.v1

Zobrazit plný text záznamu

Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

Autor: Setareh Shamsili, Robert Doornbos, Aurelia de Vries-Schultink, Cecile Geuijen, Mark Throsby, Lex Bakker, Maria Alsina, Valentina Boni, Kees Bol, Emiliano Calvo, Alwin D. R. Huitema, Jan H.M. Schellens, Bernard Doger, Martine Westendorp, Josep Tabernero

Publikováno v: Cancer Research. 76:CT050-CT050

BACKGROUND: MCLA-128 is a novel humanized full length IgG1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity that targets the transmembrane tyrosine kinase receptors, HER2 and HER3 present on a variety of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6370e324d8fe4a8377951c659ca60f0f
https://doi.org/10.1158/1538-7445.am2016-ct050

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání